- Home
- NAK vs IMTX Comparison
NAK vs IMTX Comparison
Compare NAK & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAK
- IMTX
- Stock Information
- Founded
- NAK 1983
- IMTX N/A
- Country
- NAK Canada
- IMTX Germany
- Employees
- NAK 12
- IMTX N/A
- Industry
- NAK Precious Metals
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAK Basic Materials
- IMTX Health Care
- Exchange
- NAK Nasdaq
- IMTX Nasdaq
- Market Cap
- NAK 522.4M
- IMTX 579.8M
- IPO Year
- NAK 2002
- IMTX N/A
- Fundamental
- Price
- NAK $1.05
- IMTX $4.36
- Analyst Decision
- NAK Strong Buy
- IMTX Strong Buy
- Analyst Count
- NAK 1
- IMTX 4
- Target Price
- NAK $1.30
- IMTX $16.67
- AVG Volume (30 Days)
- NAK 5.9M
- IMTX 420.3K
- Earning Date
- NAK 05-19-2025
- IMTX 05-20-2025
- Dividend Yield
- NAK N/A
- IMTX N/A
- EPS Growth
- NAK N/A
- IMTX N/A
- EPS
- NAK N/A
- IMTX 0.14
- Revenue
- NAK N/A
- IMTX $161,336,577.00
- Revenue This Year
- NAK N/A
- IMTX N/A
- Revenue Next Year
- NAK N/A
- IMTX $4.92
- P/E Ratio
- NAK N/A
- IMTX $29.94
- Revenue Growth
- NAK N/A
- IMTX 188.60
- 52 Week Low
- NAK $0.27
- IMTX $3.30
- 52 Week High
- NAK $1.29
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- NAK 50.55
- IMTX 49.60
- Support Level
- NAK $1.03
- IMTX $3.94
- Resistance Level
- NAK $1.16
- IMTX $5.41
- Average True Range (ATR)
- NAK 0.09
- IMTX 0.34
- MACD
- NAK -0.02
- IMTX -0.02
- Stochastic Oscillator
- NAK 45.45
- IMTX 41.50
About NAK Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.